These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32954653)

  • 1. Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.
    Khorana AA; Kuderer NM; McCrae K; Milentijevic D; Germain G; Laliberté F; MacKnight SD; Lefebvre P; Lyman GH; Streiff MB
    Cancer Med; 2020 Nov; 9(21):8062-8073. PubMed ID: 32954653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare costs of patients with cancer stratified by Khorana score risk levels.
    Khorana AA; Kuderer NM; McCrae K; Milentijevic D; Germain G; Laliberté F; MacKnight SD; Lefebvre P; Lyman GH; Streiff MB
    J Med Econ; 2021; 24(1):866-873. PubMed ID: 34181497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting outcomes in patients with cancer and atrial fibrillation.
    Gutierrez A; Patell R; Rybicki L; Khorana AA
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719860676. PubMed ID: 31319783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
    Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
    J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study.
    Douce DR; Holmes CE; Cushman M; MacLean CD; Ades S; Zakai NA
    J Thromb Haemost; 2019 Dec; 17(12):2152-2159. PubMed ID: 31423717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
    Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
    Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool.
    Patell R; Rybicki L; McCrae KR; Khorana AA
    Am J Hematol; 2017 Jun; 92(6):501-507. PubMed ID: 28240823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Khorana Score for Prediction of Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
    Iqbal U; Elsayed AS; Ozair S; Jing Z; James G; Li Q; Hussein AA; Guru KA
    J Endourol; 2021 Jun; 35(6):821-827. PubMed ID: 33218263
    [No Abstract]   [Full Text] [Related]  

  • 9. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
    Cohen AT; Katholing A; Rietbrock S; Bamber L; Martinez C
    Thromb Haemost; 2017 Jan; 117(1):57-65. PubMed ID: 27709226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
    Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
    J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
    Kuderer NM; Poniewierski MS; Culakova E; Lyman GH; Khorana AA; Pabinger I; Agnelli G; Liebman HA; Vicaut E; Meyer G; Shepherd FA
    Oncologist; 2018 Feb; 23(2):247-255. PubMed ID: 28951500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer.
    Giustozzi M; Curcio A; Weijs B; Field TS; Sudikas S; Katholing A; Wallenhorst C; Weitz JI; Martinez C; Cohen AT
    Thromb Haemost; 2020 May; 120(5):847-856. PubMed ID: 32369855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort.
    Blix K; Gran OV; Severinsen MT; Cannegieter SC; Jensvoll H; Overvad K; Hammerstrøm J; Tjønneland A; Naess IA; Braekkan SK; Rosendaal FR; Kristensen SR; Hansen JB
    J Thromb Haemost; 2018 Jul; 16(7):1327-1335. PubMed ID: 29691978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
    Mrozinska S; Cieslik J; Broniatowska E; Malinowski KP; Undas A
    J Thromb Haemost; 2019 Nov; 17(11):1912-1922. PubMed ID: 31323706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
    Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
    J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry.
    Alatri A; Mazzolai L; Font C; Tafur A; Valle R; Marchena PJ; Ballaz A; Tiraferri E; Font L; Monreal M; Riete Investigators T
    Thromb Haemost; 2017 Jul; 117(8):1630-1636. PubMed ID: 28517021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy.
    Tera Y; Suh YJ; Fainchtein K; Agrawal A; Mates M; Othman M
    Am J Hematol; 2024 Apr; 99 Suppl 1():S19-S27. PubMed ID: 38425173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-based Observational Experience.
    Ahmed G; Nasir HG; Hall K; Weissmann L
    Cureus; 2020 Apr; 12(4):e7883. PubMed ID: 32489737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.
    Fuentes HE; Oramas DM; Paz LH; Wang Y; Andrade XA; Tafur AJ
    J Gastrointest Cancer; 2018 Dec; 49(4):415-421. PubMed ID: 28634671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
    Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
    Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.